Skip to content
PatentBrief
Get alertsTop ↑

How to Diagnose Cancer Better Using Multiple Blood Markers and Patient Data

This patent describes a method for improving cancer diagnosis by combining measurements of several biological markers with patient-specific information like age or body mass, transforming them into a special score, and then comparing that score to a model of known cancer cases.

ActiveExpires 2043Owned by OTRACESInvented by Keith LINGENFELTER, Mohsen Marefat, Galina KRASIK

Original patent title: “Method for improving disease diagnosis using measured analytes”

Plain-English explanation by SahiLast reviewed · November 6, 2026

This patent describes a method for improving cancer diagnosis by combining measurements of several biological markers with patient-specific information like age or body mass, transforming them into a special score, and then comparing that score to a model of known cancer cases. Owned by OTRACES with 22 claims, and it is expected to expire in 2043.

Coverage

What does this patent actually cover?

This method aims to improve cancer diagnosis and treatment by analyzing a subject's biological samples. First, it receives concentrations of at least three specific biological markers, called analytes, from a patient's sample (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1a). Then, it selects additional patient details, known as meta-variables, such as age, body mass, or menopausal status, which are known to vary in the general population (Claim 1b, Claim 2). These analyte concentrations are then transformed, using both population data and the selected meta-variables, into a special unitless number called a "pseudo-concentration" for each analyte (Claim 1c). These pseudo-concentrations are scored against a pre-built model of pseudo-concentrations from people known to have or not have the disease (Claim 1d). Finally, based on this score, the method diagnoses whether the subject has cancer, provided the diagnostic model performs with at least 75% accuracy in avoiding false positives and negatives, and then suggests administering anti-cancer drugs (Claim 1e). For example, a doctor could use this system to get a more accurate cancer diagnosis for a patient by inputting their blood test results and their age, and the system would output a diagnosis and treatment recommendation.

The gap

What does this patent NOT cover?

  • Does not cover diagnostic methods that use fewer than three predetermined analytes.
  • Does not cover diagnostic methods that do not incorporate meta-variables specific to the subject's population, like age or body mass.
  • Does not cover diagnostic methods where the raw analyte concentrations are not transformed into unitless, clinically predictive pseudo-concentrations.
  • Does not cover diagnostic models with a false negative and false positive performance worse than 75%.
  • Does not cover diagnostic methods that only provide a diagnosis without also including the administration of anti-cancer drugs.

These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.

Key facts

Patent numberUS 20230274838
StatusActive
FieldBiotech & Medicine
AssigneeOTRACES
InventorsKeith LINGENFELTER, Mohsen Marefat, Galina KRASIK
Filed2023
Expires2043
Claims22
Times cited0
LitigationNone on record
Value · $39K–$125KMinimal

What made this novel

The truly clever part is transforming raw analyte concentrations into "pseudo-concentrations" by factoring in patient-specific meta-variables and population distribution characteristics. This normalizes the data, making the diagnostic score more robust and less prone to variations caused by individual differences, thus improving diagnostic accuracy.

The Patent Drawing

Representative patent drawing for Method for improving disease diagnosis using measured analytes (US 20230274838)
Representative figure · US 20230274838All figures on Google Patents →
Method for improving disease d…(Primary claim)biotechpharmaceuticalsoftwareai mltelecommunications

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.

Where you've seen this

Real-world examples

01

Personalized cancer diagnostic panels

02

AI-powered medical diagnostic systems

03

Advanced blood tests for early disease detection

04

Precision oncology treatment planning tools

Why it matters

The bigger picture

Accurate and early cancer diagnosis is critical for effective treatment. This patent matters because it proposes a way to make diagnostic tests more precise by accounting for individual patient characteristics and population differences, rather than relying solely on raw biomarker levels. By integrating meta-variables, it aims to reduce misdiagnoses, which can lead to better patient outcomes and more targeted treatment plans. This approach could help personalize medicine by making diagnostic results more relevant to each unique patient.

Filed

May 5, 2023

Market context

Who's building on this

Companies in this space

OTRACES, the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is likely developing or licensing technologies based on this method. Companies like Foundation Medicine, Guardant Health, and Tempus AI are actively working in the space of precision oncology, leveraging advanced diagnostics and AI to personalize cancer treatment. These companies focus on analyzing complex biological data and patient characteristics to improve diagnostic accuracy and guide therapeutic decisions.

Market impact

This patent could contribute to a market shift towards more personalized and accurate cancer diagnostics. By integrating patient-specific data, it aims to reduce diagnostic errors, potentially leading to earlier and more effective interventions. This approach could influence how new diagnostic tests are developed and validated, pushing the industry towards more sophisticated, data-driven models that go beyond simple biomarker thresholds. It also reinforces the trend of combining diagnostics with treatment recommendations.

Claim 1 — Plain English

What this patent covers

This method aims to improve cancer diagnosis and treatment by analyzing a subject's biological samples. First, it receives concentrations of at least three specific biological markers, called analytes, from a patient's sample (Claim 1a). Then, it selects additional patient details, known as meta-variables, such as age, body mass, or menopausal status, which are known to vary in the general population (Claim 1b, Claim 2). These analyte concentrations are then transformed, using both population data and the selected meta-variables, into a special unitless number called a "pseudo-concentration" for each analyte (Claim 1c). These pseudo-concentrations are scored against a pre-built model of pseudo-concentrations from people known to have or not have the disease (Claim 1d). Finally, based on this score, the method diagnoses whether the subject has cancer, provided the diagnostic model performs with at least 75% accuracy in avoiding false positives and negatives, and then suggests administering anti-cancer drugs (Claim 1e). For example, a doctor could use this system to get a more accurate cancer diagnosis for a patient by inputting their blood test results and their age, and the system would output a diagnosis and treatment recommendation.

The clever bit

The truly clever part is transforming raw analyte concentrations into "pseudo-concentrations" by factoring in patient-specific meta-variables and population distribution characteristics. This normalizes the data, making the diagnostic score more robust and less prone to variations caused by individual differences, thus improving diagnostic accuracy.

What it does not cover

  • Does not cover diagnostic methods that use fewer than three predetermined analytes.
  • Does not cover diagnostic methods that do not incorporate meta-variables specific to the subject's population, like age or body mass.
  • Does not cover diagnostic methods where the raw analyte concentrations are not transformed into unitless, clinically predictive pseudo-concentrations.
  • Does not cover diagnostic models with a false negative and false positive performance worse than 75%.
  • Does not cover diagnostic methods that only provide a diagnosis without also including the administration of anti-cancer drugs.

Patent timeline

Filing

Application submitted to the patent office

Expiration

Patent enters public domain

PatentBrief Score

Impact Score

Limited data

Citation count

0/40

No citations yet

Claim breadth

15/20

Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →

Recency

0/20

Older than 20 years

Assignee scale

0/20

Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →

PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.

Heuristic Value Estimate

What this patent might be worth

Minimal

$39K – $125K

Midpoint $78K · 16.4 yr remaining · industry ×2.0

Adjust inputs →

Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.

Claim text not yet imported for this patent

The original legal language

Original claims

22 claims as filed with the patent office.

Concepts involved

ClaimPrior artNon-obviousnessNoveltySpecificationAssigneePatent term

Citations

Patent lineage

Cites earlier patents

1

earlier patents this invention cites as foundations

View prior art →

Cite this patent

LINGENFELTER, K., Marefat, M., & KRASIK, G. How to Diagnose Cancer Better Using Multiple Blood Markers and Patient Data (U.S. Patent No. 20,230,274,838). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/20230274838/method-for-improving-disease-diagnosis-using-measured-analytes

Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.

Embed

Add this patent to your site

Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.

<div data-patentlens-widget data-patent-number="US20230274838"></div>
<script src="https://patentbrief.org/embed.js" async></script>

Stay in the loop

Get a weekly digest of new patents.

One email per week. No spam. Unsubscribe anytime.

Keep exploring

Related patents you should know

US 4683195 · 1987

How to Make Billions of Copies of a DNA Segment

This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.

Cetus Corp

US 8697359 · 2014

How to Edit Genes in Human Cells Using an Engineered CRISPR System

This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.

Massachusetts Institute of Technology

US 7657849 · 2010

How the iPhone's Slide-to-Unlock Gesture Works

Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.

Apple Inc

US 4733665 · 1988

How Doctors Implant a Permanent Stent Using a Balloon

This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.

Expandable Grafts Partnership

US 4965188 · 1990

How to Make Many Copies of a DNA Piece with Heat

This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.

Cetus Corp

US 4235871 · 1980

How to Encapsulate Active Materials in Lipid Bubbles Efficiently

This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.

Individual

Semantically similar

You might also find these interesting

SEARCH ALL

More to explore

More in Biotech & Medicine

Browse all Biotech & Medicine

New to patents?

What is a patent?How to read a patentAnatomy of a claimHow strong is this patent?What the citations meanWhat it doesn't coverBiotech PatentsPatent glossary
Explore the landscape:biotech patents →pharmaceutical patents →software patents →

Common Questions

Frequently Asked Questions

What does How to Diagnose Cancer Better Using Multiple Blood Markers and Patient Data cover?

This patent describes a method for improving cancer diagnosis by combining measurements of several biological markers with patient-specific information like age or body mass, transforming them into a special score, and then comparing that score to a model of known cancer cases.

Who owns patent US 20230274838?

This patent is owned by OTRACES.

When does this patent expire?

This patent is expected to expire on May 5, 2043, when the invention enters the public domain.

What problem does this patent solve?

Accurate and early cancer diagnosis is critical for effective treatment. This patent matters because it proposes a way to make diagnostic tests more precise by accounting for individual patient characteristics and population differences, rather than relying solely on raw biomarker levels. By integrating meta-variables, it aims to reduce misdiagnoses, which can lead to better patient outcomes and more targeted treatment plans. This approach could help personalize medicine by making diagnostic results more relevant to each unique patient.

What does this patent NOT cover?

Does not cover diagnostic methods that use fewer than three predetermined analytes.

Patent monitoring

Get notified when OTRACES files a new patent

Get notified when this company files a new patent. Weekly digest · Confirm via email · Unsubscribe anytime.

Last reviewed: November 6, 2026 · PatentBrief is not a law firm and this is not legal advice.